The Lancet

Intraperitoneal antineoplastic drug delivery: rationale and results

Cleveland Clinic Taussig Cancer Center, and the Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, OH, USA The use of intraperitoneal drug delivery in the treatment of ...
Santé log

Theolytics Announces First Patient Dosed in the OCTOPOD-IP Trial, a US Phase 1 Trial with THEO-260, a Novel Oncolytic Immunotherapy Targeting Ovarian Cancer

OCTOPOD-IP is being conducted to investigate intraperitoneal (IP) administration of THEO-260 in women with advanced platinum-resistant ovarian cancer Recruitment on track in OCTOPOD-IV, a Phase 1/2a ...
ascopubs.org

Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial

Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis We constructed a Markov ...
Medical Dialogues

Intraperitoneal Therapy Superior to multiple insulin injections in Early Diabetic Nephropathy: Study

Researchers have found in a new study that Intraperitoneal (IP) therapy demonstrated better efficacy than MSII in improving ...
Europe PMC

Intraperitoneal compared with intravenous meropenem for peritoneal dialysis-related peritonitis.

Peritonitis is a frequent complication of peritoneal dialysis (PD) and the most common cause of PD failure. The mainstay of treatment is antimicrobial therapy. Guidelines advocate intraperitoneal (IP) ...
ascopubs.org

Update on Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer

In clinical practice, only a few risk factors remain that can be modified based on the decisions of patients and their physicians. The surgical decision making and chemotherapy administration choices, ...
Europe PMC

Phase I study of intraperitoneal irinotecan combined with palliative systemic chemotherapy in patients with colorectal peritoneal metastases.

Patients with colorectal peritoneal metastases who are not eligible for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) owing to extensive peritoneal disease have a ...
BMJ

Efficacy and safety of intraperitoneal dexamethasone on postoperative nausea and vomiting following laparoscopy: study protocol for a systematic review and meta-analysis

Introduction Intraperitoneal dexamethasone has been reported to be effective to reduce the incidence of postoperative nausea and vomiting (PONV). Therefore, this meta-analysis will analyse the ...
Nature

Intraperitoneal chemotherapy as adjuvant treatment to prevent peritoneal carcinomatosis of colorectal cancer origin: a systematic review

Peritoneal carcinomatosis (PC) of colorectal cancer (CRC) origin is associated with poor outcome. This systematic review evaluates the available evidence about adjuvant (hyperthermic) intraperitoneal ...
BMJ

Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases: protocol of the multicentre, open-label ...

Introduction The peritoneum is the second most affected organ for the dissemination of colorectal cancer (CRC). Patients with colorectal peritoneal metastases (CPM) face a poor prognosis, despite the ...
Medscape

Intraperitoneal Therapy for Peritoneal Cancer

Cancers originating from organs in the peritoneal cavity (e.g., ovarian, pancreatic, colorectal, gastric and liver) account for approximately 250,000 new cancer cases annually in the USA. Peritoneal ...